{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:12:48Z","timestamp":1764828768356,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dihydropyrimidine dehydrogenase (DPD) status is an indicator of a marked risk for toxicity following fluoropyrimidine (FP)-based chemotherapy. This notion is well-established for low DPD status but little is known about the clinical impact of high DPD activity. This study examined the possible link between high intrinsic lymphocytic DPD activity and overall survival, progression free survival and response to FP-based treatment in patients treated in our institution.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Lymphocytic DPD activity was assessed in a group of 136 patients receiving FP-based chemotherapy from 2004 to 2016. There were 105 digestive (77.2%), 24 breast (17.6%) and 7 head and neck cancers (5.2%). Cox or logistic regression models were applied with adjustment on all confounding factors that could modify OS, PFS or response. All models were stratified on the three cancer locations. A cut-off for DPD activity was assessed graphically and analytically.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>An optimal cut-off for DPD activity at 0.30\u2009nmol\/min\/mg protein was identified as the best value for discriminating survivals and response. In multivariate analysis, individual lymphocytic DPD activity was significantly related to overall survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.013; HR: 3.35 CI95%[1.27\u20138.86]), progression-free survival (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; HR: 3.15 CI95%[1.75\u20135.66]) and response rate (<jats:italic>p<\/jats:italic>\u2009=\u20090.033; HR: 0.33 CI95%[0.12\u20130.92]) with a marked detrimental effect associated with high DPD activity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>DPD status screening should result in a two-pronged approach with FP dose reduction in case of low intrinsic DPD and, inversely, an increased FP dose for high intrinsic DPD. In a context of personalized FP-based treatment, this innovative strategy needs to be prospectively validated.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-020-06907-0","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T17:04:17Z","timestamp":1589821457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["DPD status and fluoropyrimidines-based treatment: high activity matters too"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6841-4571","authenticated-orcid":false,"given":"Emmanuel","family":"Chamorey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Francois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Peyrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Barranger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Bozec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Largillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ophelie","family":"Cassuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Viotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Schiappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Milano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,18]]},"reference":[{"issue":"9","key":"6907_CR1","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","volume":"74","author":"SM Offer","year":"2014","unstructured":"Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014;74(9):2545\u201354.","journal-title":"Cancer Res"},{"issue":"11","key":"6907_CR2","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","volume":"12","author":"MC Etienne","year":"1994","unstructured":"Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994;12(11):2248\u201353.","journal-title":"J Clin Oncol"},{"issue":"22","key":"6907_CR3","first-page":"5433","volume":"53","author":"Z Lu","year":"1993","unstructured":"Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 1993;53(22):5433\u20138.","journal-title":"Cancer Res"},{"key":"6907_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/8904_2018_138","volume":"45","author":"ABP van Kuilenburg","year":"2019","unstructured":"van Kuilenburg ABP, Meijer J, Meinsma R, Perez-Duenas B, Alders M, Bhuiyan ZA, et al. Dihydropyrimidine dehydrogenase deficiency: Homozygosity for an extremely rare variant in DPYD due to Uniparental Isodisomy of chromosome 1. JIMD Rep. 2019;45:65\u20139.","journal-title":"JIMD Rep"},{"issue":"5","key":"6907_CR5","doi-asserted-by":"publisher","first-page":"e0175998","DOI":"10.1371\/journal.pone.0175998","volume":"12","author":"MC Etienne-Grimaldi","year":"2017","unstructured":"Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, et al. New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS One. 2017;12(5):e0175998.","journal-title":"PLoS One"},{"issue":"16","key":"6907_CR6","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>a\/HapB3, and c.1601G>a as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639\u201350.","journal-title":"Lancet Oncol"},{"issue":"3","key":"6907_CR7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.bbadis.2016.12.010","volume":"1863","author":"AB van Kuilenburg","year":"2017","unstructured":"van Kuilenburg AB, Meijer J, Maurer D, Dobritzsch D, Meinsma R, Los M, et al. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing. Biochim Biophys Acta. 2017;1863(3):721\u201330.","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"6907_CR8","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1002\/cncr.26595","volume":"118","author":"Y Wettergren","year":"2012","unstructured":"Wettergren Y, Carlsson G, Odin E, Gustavsson B. Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. Cancer. 2012;118(11):2935\u201343.","journal-title":"Cancer."},{"issue":"7","key":"6907_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","volume":"40","author":"AB van Kuilenburg","year":"2004","unstructured":"van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7):939\u201350.","journal-title":"Eur J Cancer"},{"issue":"11","key":"6907_CR10","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","volume":"19","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Lunenburg C, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19(11):1459\u201367.","journal-title":"Lancet Oncol"},{"issue":"10","key":"6907_CR11","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/0959-8049(94)00216-R","volume":"30A","author":"A Beck","year":"1994","unstructured":"Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer. 1994;30A(10):1517\u201322.","journal-title":"Eur J Cancer"},{"issue":"7","key":"6907_CR12","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.1995.13.7.1663","volume":"13","author":"MC Etienne","year":"1995","unstructured":"Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol. 1995;13(7):1663\u201370.","journal-title":"J Clin Oncol"},{"issue":"1","key":"6907_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0959-8049(99)00211-7","volume":"36","author":"G Milano","year":"2000","unstructured":"Milano G, McLeod HL. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? Eur J Cancer. 2000;36(1):37\u201342.","journal-title":"Eur J Cancer"},{"key":"6907_CR14","first-page":"9202676","volume":"2017","author":"C Zhang","year":"2017","unstructured":"Zhang C, Liu H, Ma B, Song Y, Gao P, Xu Y, et al. The impact of the expression level of Intratumoral Dihydropyrimidine dehydrogenase on chemotherapy sensitivity and survival of patients in gastric Cancer: a meta-analysis. Dis Markers. 2017;2017:9202676.","journal-title":"Dis Markers"},{"issue":"1","key":"6907_CR15","first-page":"197","volume":"50","author":"BE Harris","year":"1990","unstructured":"Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 1990;50(1):197\u2013201.","journal-title":"Cancer Res"},{"issue":"24","key":"6907_CR16","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1016\/0006-2952(88)90349-8","volume":"37","author":"BE Harris","year":"1988","unstructured":"Harris BE, Song RL, He YJ, Soong SJ, Diasio RB. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. Biochem Pharmacol. 1988;37(24):4759\u201362.","journal-title":"Biochem Pharmacol"},{"key":"6907_CR17","unstructured":"INCA HADSHIdC. Recherche de d\u00e9ficit en dihydropyrimidine d\u00e9shydrog\u00e9nase en vue de pr\u00e9venir certaines toxicit\u00e9s s\u00e9v\u00e8res survenant sous traitement comportant des fluoropyrimidines. HAS. 2018."},{"issue":"2","key":"6907_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical Pharmacogenetics implementation consortium (CPIC) guideline for Dihydropyrimidine dehydrogenase genotype and Fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103(2):210\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"6907_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/1535-7163.MCT-13-0878","volume":"13","author":"SM Offer","year":"2014","unstructured":"Offer SM, Butterfield GL, Jerde CR, Fossum CC, Wegner NJ, Diasio RB. microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther. 2014;13(3):742\u201351.","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"6907_CR20","doi-asserted-by":"publisher","first-page":"6362","DOI":"10.1158\/0008-5472.CAN-16-1306","volume":"76","author":"R Wu","year":"2016","unstructured":"Wu R, Nie Q, Tapper EE, Jerde CR, Dunlap GS, Shrestha S, et al. Histone H3K27 Trimethylation modulates 5-fluorouracil resistance by inhibiting PU.1 binding to the DPYD promoter. Cancer Res. 2016;76(21):6362\u201373.","journal-title":"Cancer Res"},{"issue":"1","key":"6907_CR21","doi-asserted-by":"publisher","first-page":"9711","DOI":"10.1038\/s41598-017-09859-x","volume":"7","author":"P Gokare","year":"2017","unstructured":"Gokare P, Finnberg NK, Abbosh PH, Dai J, Murphy ME, El-Deiry WS. P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting. Sci Rep. 2017;7(1):9711.","journal-title":"Sci Rep"},{"issue":"11","key":"6907_CR22","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1038\/bjc.2014.213","volume":"110","author":"MC Etienne-Grimaldi","year":"2014","unstructured":"Etienne-Grimaldi MC, Mahamat A, Chazal M, Laurent-Puig P, Olschwang S, Gaub MP, et al. Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. Br J Cancer. 2014;110(11):2728\u201337.","journal-title":"Br J Cancer"},{"issue":"11","key":"6907_CR23","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jnci\/djr153","volume":"103","author":"FA Sinicrope","year":"2011","unstructured":"Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103(11):863\u201375.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"6907_CR24","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41416-018-0004-2","volume":"118","author":"NO Elander","year":"2018","unstructured":"Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, et al. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Br J Cancer. 2018;118(7):947\u201354.","journal-title":"Br J Cancer"},{"issue":"13","key":"6907_CR25","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","volume":"26","author":"E Gamelin","year":"2008","unstructured":"Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(13):2099\u2013105.","journal-title":"J Clin Oncol"},{"issue":"6","key":"6907_CR26","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1200\/JCO.1994.12.6.1291","volume":"12","author":"G Milano","year":"1994","unstructured":"Milano G, Etienne MC, Renee N, Thyss A, Schneider M, Ramaioli A, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol. 1994;12(6):1291\u20135.","journal-title":"J Clin Oncol"},{"issue":"3","key":"6907_CR27","first-page":"507","volume":"2","author":"M Chazal","year":"1996","unstructured":"Chazal M, Etienne MC, Renee N, Bourgeon A, Richelme H, Milano G. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res. 1996;2(3):507\u201310.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"6907_CR28","doi-asserted-by":"publisher","first-page":"E4442","DOI":"10.1073\/pnas.1618714114","volume":"114","author":"TT Schmidt","year":"2017","unstructured":"Schmidt TT, Reyes G, Gries K, Ceylan CU, Sharma S, Meurer M, et al. Alterations in cellular metabolism triggered by URA7 or GLN3 inactivation cause imbalanced dNTP pools and increased mutagenesis. Proc Natl Acad Sci U S A. 2017;114(22):E4442\u2013E51.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"6907_CR29","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.cell.2018.07.019","volume":"174","author":"JS Lee","year":"2018","unstructured":"Lee JS, Adler L, Karathia H, Carmel N, Rabinovich S, Auslander N, et al. Urea cycle Dysregulation generates clinically relevant genomic and biochemical signatures. Cell. 2018;174(6):1559\u201370 e22.","journal-title":"Cell."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06907-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-06907-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06907-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T23:14:23Z","timestamp":1621293263000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06907-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,18]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6907"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06907-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2020,5,18]]},"assertion":[{"value":"2 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was declared to the Commission Nationale Informatique et Libert\u00e9 (CNIL N\u00b017002) and all patients agreed that their data could be used for retrospective biomedical study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"436"}}